Article Text

Download PDFPDF
1067 FaTE score: a prognostic score for endometrial cancer from MITO24 study
  1. Alberto Farolfi1,
  2. Valentina Tuninetti2,
  3. Emanuela Scarpi1,
  4. Vera Loizzi3,
  5. Giorgia Mangili4,
  6. Caterina Godina5,
  7. Claudia Casanova6,
  8. Jole Ventriglia7,
  9. Sandro Pignata7,
  10. Cormio Gennaro8,
  11. Giorgio Valabrega2 and
  12. Ugo De Giorgi1
  1. 1IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy
  2. 2Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy
  3. 3Università di Bari, Bari, Italy
  4. 4IRCCS San Raffaele Hospital, Milan, Italy
  5. 5IRCCS Burlo Garofolo, Trieste, Italy
  6. 6Santa Maria delle Croci Hospital, Ravenna, Italy
  7. 7Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy
  8. 8Gynecologic Oncology Istituto Tumori Giovanni Paolo II - IRCCS, University of Bari, Bari, Italy


Introduction/Background Molecular classification of endometrial cancer (EC) has entered clinical use and possess prognostic information in early stages. We sought to identify a clinical prognostic score for advanced EC.

Methodology A total of 114 EC patients were analyzed in this multicenter retrospective study. All patients included in the study underwent chemotherapy. A Weibull multiple regression model was adopted to evaluate the combined impact of clinical data on overall survival (OS) and to obtain a prognostic score. Each variables is allotted a ’partial score’ that depends on the size of the regression coefficient. Total scores can range between 0 and 6.1 and assign patients to three different risk groups according to a 36-months survival probability: group 1, >70%; group 2, 30%-70%; and group 3, <30%. We estimated OS probabilities by the exponential model and by the Kaplan-Meier method.

Results In multivariate analysis grade, ECOG performance status (PS), platelets count and time from surgery to the start of 1st line chemotherapy were predictive for OS and PFS. By applying the FaTE score, three risk groups were identified: group 1 (47.4% of patients) with a score of ≤1.0, group 2 (30.7%) with a score of 1.1–2.4 and group 3 (21.9%) with a score of ≥2.5. Median OS (mOS) was significantly different among the three risk groups: risk group 1, mOS not reached (nr); risk group 2, 42.1 months (95%CI 24.1-nr) and risk group 3, 11.5 months (95%CI 7.4–28.6), p<0.0001. 36-months survival probability was 88% (95% CI, 78–98) for risk group 1, 56% (95% CI, 37–75) for risk group 2 and 28% (95% CI, 9–47) for risk group 3. The c-index score was 0.839 (95%CI 0.745 – 0.932).

Conclusion This analysis demonstrated that this easy-to-use tool, at no additional costs, provides accurate prognostic stratification for EC. Validation of our FaTE score is warranted.

Disclosures A.F. has received personal honoraria for lectures from Astrazeneca, GSK-Tesaro, Clovis, and advisory board from Jannsen, Astrazeneca, GSK-Tesaro.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.